{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"None"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Mild"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Moderate"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Severe"}],"title":"Right eye, Worst findings"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"None"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Mild"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Moderate"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Severe"}],"title":"Left eye, Worst findings"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"None"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Mild"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Moderate"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Severe"}],"title":"Worst eye, Worst findings"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}],"title":"None"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"Mild"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Moderate"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Severe"}],"title":"Right eye, Most frequent findings"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}],"title":"None"},{"measurements":[{"groupId":"OG000","value":"13"}],"title":"Mild"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Moderate"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Severe"}],"title":"Left eye, Most frequent findings"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}],"title":"None"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"Mild"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Moderate"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Severe"}],"title":"Worst eye, Most frequent findings"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Participants with worse case punctate keratopathy findings post baseline at any ocular exam by right eye, left eye and worse eye are presented as none, mild, moderate and severe. Worse eye indicates the eye with the worst visual acuity. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 178 weeks","title":"Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings","type":"SECONDARY","unitOfMeasure":"Participants"}